Information for GPs

For all participants randomized into the Zio Patch arm of the study; once the patch has been returned, the study team will send a letter to the participant’s GP practice containing information on the presence and duration of any episodes of atrial fibrillation. Participants will also receive a copy of this letter for their information. Clinically significant findings will be reported directly to the GP. The participant’s subsequent management will be at the discretion of their GP, allowing the doctor and participant to discuss their management strategy (including anticoagulation) independently. The study team will not directly initiate treatment or act on the information from the Zio Patch data.

For further information, the 2016 European Society of Cardiology guidelines on the Management of Atrial Fibrillation can be found on the ESC website.

There is also a Clinical Knowledge Summary produced by NICE available on the NICE website.

Download the Patient Information Leaflet and the AMALFI protocol for more information.